Pro Medicus Ltd

PME: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
bN!LOCK|>!rmLOCK|!P!m#dF

Pro Medicus Earnings: Margins Improve but Key Academic Hospital Market Is Limited

Pro Medicus’ fiscal 2025 EBIT grew 40%, with revenue up 32% on contract wins and EBIT margin expanding 450 basis points to 74%. Revenue from new contracts is outstripping cost growth, with new staff for research and development making up most of the year’s increase in costs.

Sponsor Center